News | August 15, 2024
Evonik expands its formulation capabilities for lipid nanoparticles
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Strong topline growth driven by solid performance across key brands.
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
Subscribe To Our Newsletter & Stay Updated
